Targeting cellular senescence with senolytics to improve skeletal health in older humans
Description: PROJECT NARRATIVE This R21 application focuses on osteoporosis, a common late-life disease that often co-exists with other chronic diseases and leads to ~2 million fractures and ~$17 billion in healthcare costs annually. We hypothesize that targeting senescent cells, using “senolytics” – i.e., drugs that selectively induce senescent cell apoptosis, will improve skeletal health in older humans. If our hypothesis is correct, the impact on clinical practice and our healthcare system would be substantial and potentially of paramount importance.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R21
Start date: 2020-02-15
End date: 2023-01-31
Investigator: JOSHUA NICHOLAS FARR
Institution: MAYO CLINIC ROCHESTER
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 24
Funder award ID: R21AG065868
OpenAlex ID: G6524323407